IMPLEMENTATION OF A HUB PROTOCOL FOR REDUCING COMPLICATIONS IN SPINAL CORD AND DORSAL ROOT GANGLION STIMULATION: REAL-WORLD EXPERIENCE FROM THE EASTERN SICILY PAIN MANAGEMENT HUB CENTER
S. Zappalà1, S. Stimolo2, M. Maria3, S. Brundo3, S. Caramma3 | 1Università di padova, Padova, Italy; 2Università di Padova, Italy; 3Policlinico G. Rodolico- San Marco, Catania, Italy
Abstract
Introduction. Spinal cord stimulation (SCS) and dorsal root ganglion stimulation (DRGS) are cornerstones of neuromodulation for refractory chronic neuropathic pain. However, these procedures historically carry non-negligible infectious (3%–6%), neurological (2.31%), and mechanical complication rates that jeopardize efficacy and increase healthcare costs. This study evaluates the efficacy and safety of a standardized, multiphasic institutional protocol implemented at the Hub Center of Catania to minimize such adverse events in real-world practice.
Methods. A retrospective observational study (January 2024–June 2025) evaluated 66 patients undergoing definitive SCS/DRGS implantation after a 30-day trial phase with >50% pain relief. The institutional protocol standardized three main phases: Pre-operative Phase Comprehensive clinical assessment, including psychological and functional evaluation for clinical eligibility , metabolic optimization (fasting glucose <180 mg/dl, smoking cessation ≥ 4 weeks, BMI <35). Neuroanatomical eligibility via CT/MRI required a posterior epidural space and lateral recess width >3 mm. Antithrombotic therapy was managed per NACC/INS guidelines, alongside S. aureus nasal PCR screening and antiseptic showers. Intra-operative & Surgical Phase: Antibiotic prophylaxis, chlorhexidine skin antisepsis, and a double-glove technique before handling the implantable pulse generator (IPG). Leads were placed fluoroscopically via a paramedian epidural approach. Device stability was secured using active anchors, deep fascial silk sutures, and an epifascial strain-relief loop. The IPG pocket was tailored precisely to eliminate dead spaces, followed by layered anatomical closure (deep interrupted and intradermal sutures). Post-operative Phase: Wound care, patient/caregiver education, and clinical/telemetric follow-ups at 7, 14, 21, and 30 days (definitive implant, T1), 3 months (T2), 6 months (T3), and 1 year (T4).
Results. The cumulative 1-year (T4) complication rate was 3.03% (n=2/66). Both superficial and deep surgical site infections were 0%, showing a statistically significant reduction compared to historical data (p<0.05). Neurological, hemorrhagic, and CSF leak complications were also 0%. Adverse events were exclusively mechanical (3.03%, n=2): one DRGS electrode fracture at T3 due to trauma, and one SCS lead migration at T4 following a domestic accident. The rate of intrinsic complications directly attributable to failures in the standardized clinical pathway was 0%.
Conclusions. Systematic application of an evidence-based, standardized HUB protocol eliminates clinical variability, reducing intrinsic procedural complications to near-zero levels while maximizing patient safety and healthcare efficiency.
Methods. A retrospective observational study (January 2024–June 2025) evaluated 66 patients undergoing definitive SCS/DRGS implantation after a 30-day trial phase with >50% pain relief. The institutional protocol standardized three main phases: Pre-operative Phase Comprehensive clinical assessment, including psychological and functional evaluation for clinical eligibility , metabolic optimization (fasting glucose <180 mg/dl, smoking cessation ≥ 4 weeks, BMI <35). Neuroanatomical eligibility via CT/MRI required a posterior epidural space and lateral recess width >3 mm. Antithrombotic therapy was managed per NACC/INS guidelines, alongside S. aureus nasal PCR screening and antiseptic showers. Intra-operative & Surgical Phase: Antibiotic prophylaxis, chlorhexidine skin antisepsis, and a double-glove technique before handling the implantable pulse generator (IPG). Leads were placed fluoroscopically via a paramedian epidural approach. Device stability was secured using active anchors, deep fascial silk sutures, and an epifascial strain-relief loop. The IPG pocket was tailored precisely to eliminate dead spaces, followed by layered anatomical closure (deep interrupted and intradermal sutures). Post-operative Phase: Wound care, patient/caregiver education, and clinical/telemetric follow-ups at 7, 14, 21, and 30 days (definitive implant, T1), 3 months (T2), 6 months (T3), and 1 year (T4).
Results. The cumulative 1-year (T4) complication rate was 3.03% (n=2/66). Both superficial and deep surgical site infections were 0%, showing a statistically significant reduction compared to historical data (p<0.05). Neurological, hemorrhagic, and CSF leak complications were also 0%. Adverse events were exclusively mechanical (3.03%, n=2): one DRGS electrode fracture at T3 due to trauma, and one SCS lead migration at T4 following a domestic accident. The rate of intrinsic complications directly attributable to failures in the standardized clinical pathway was 0%.
Conclusions. Systematic application of an evidence-based, standardized HUB protocol eliminates clinical variability, reducing intrinsic procedural complications to near-zero levels while maximizing patient safety and healthcare efficiency.

References
- 1. Deer T.R., et al. The Neurostimulation Appropriateness Consensus Committee (NACC)®: Recommendations for the Mitigation of Complications of Neurostimulation. Neuromodulation 2024; 27: 977–1007.
- 2. Deer T.R., et al. The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations for Surgical Technique for Spinal Cord Stimulation. Neuromodulation 2022; 25: 1–34.
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.